Bacteriostatic Antibiotics Market - Proximate and supreme causes of the bactericidal action of antibiotics

Global Bacteriostatic Antibiotics Market Analysis

Overview

Antibiotics are compounds that are found in nature or are synthesized chemically and are frequently used to treat bacterial infections. Antibiotics function by killing germs or reducing their growth (bactericidal action) (bacteriostatic effect). Bacteriostatic antibiotics stop bacteria from growing and reproducing, but they do not involve killing them.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2307

Drivers

Due to the recent clearance and introduction of innovative bacteriostatic antibiotics products in the market, the global bacteriostatic antibiotics market is projected to develop significantly during the forecast period.

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on the development, production, and monetization of innovative antibiotics for the treatment of life-threatening multidrug-resistant (MDR) infections, gained European Commission (EC) marketing approval for XERAVA infusion in September 2018. In the European Union, it is approved for the treatment of complex intra-abdominal infections (cIAI) in adults. XERAVA (Eravacycline) is a fluorocycline antibacterial medication that belongs to the tetracycline family. It is bacteriostatic towards gram-positive bacteria.

The rising frequency of bacterial and infectious diseases is likely to drive demand for bacteriostatic antibiotics, resulting in growth of the global bacteriostatic antibiotics market. As per the Centers for Disease Control and Prevention (CDC), 9,272 individuals in the U.S. were diagnosed with TB, 53,850 with salmonella, and 36,429 with Lyme disease in 2016.

Tailored Information as per niche requirement:

LIMITED TIME OFFER - Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2307

Regional Insights

Due to the existence of main players and their authorization and release of innovative bacteriostatic antibiotics drugs in the region, the North American bacteriostatic antibiotics market is set to retain a leading position in the global bacteriostatic antibiotics market and account for the largest market share during the forecast period.

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical firm located in Massachusetts, got FDA clearance in August 2018 for its new bacteriostatic antibiotics, specifically XERAVA (eravacycline), for the treatment of severe intra-abdominal infections (cIAI).

Restraints

Some of the negative effects associated with bacteriostatic antibiotics may reduce their use and slow the growth of the global bacteriostatic antibiotics market. Chloramphenicol, a bacteriostatic antibiotic, has serious side effects including bone marrow suppression, severe allergic responses, and can even cause mental issues.

Moreover, the availability of bactericidal antibiotics, which are a replacement for bacteriostatic antibiotics, may provide internal threat of replacement and impede the growth of the global bacteriostatic antibiotics market.

To get detailed table of content (ToC), please click - https://www.coherentmarketinsights.com/ongoing-insight/toc/2307

Competitive Landscape

Major companies contributing in the global bacteriostatic antibiotics market are Pfizer Inc., Sun Pharmaceutical Industries Ltd., Tetraphase Pharmaceuticals, Inc., Akorn Inc., Allergan Plc., Hikma Pharmaceuticals Plc., and Mylan N.V.

Other Related Reports:

Antibiotics and Corticosteroids Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Leishmaniasis Treatment Market, By Disease Type (Cutaneous Leishmaniasis, Visceral Leishmaniasis, Mucocutaneous Leishmaniasis), and By Drug Type (Pentavalent Antimonials, Antibiotics) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Generic Drugs Market, By Drug Type (Monoclonal Antibodies, Cytokines, Vaccines, Insulin, Peptide Hormone, Immunoglobulin, Peptide Antibiotics, Blood Factors, and Others), By Therapeutic Application (Oncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Musculoskeletal Diseases, and Others), By Route of Administration (Oral, Topical, Injectable, Intra-venous, and Others), and By Geography- (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2026

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837